Drugs / PEGylated recombinant candida urate oxidase
PEGylated recombinant candida urate oxidase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04047394 | Oct 2019 → Oct 2022 | gout | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGylated recombinant candida urate oxidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04047394 ↗ |
| Modality | Protein / enzyme biologic | “Candida utilis recombinant uricase” NCT04047394 ↗ |
| Route | Intravenous | “Intravenous injection” NCT04047394 ↗ |